vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Equity Residential (EQR). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $781.9M, roughly 1.2× Equity Residential). Equity Residential runs the higher net margin — 48.9% vs 7.7%, a 41.1% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs 2.0%). Over the past eight quarters, Equity Residential's revenue compounded faster (3.4% CAGR vs 2.6%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Equity Residential is a United States–based publicly traded real estate investment trust that invests in apartments.
ATR vs EQR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $781.9M |
| Net Profit | $74.3M | $382.1M |
| Gross Margin | — | — |
| Operating Margin | 11.0% | 50.6% |
| Net Margin | 7.7% | 48.9% |
| Revenue YoY | 13.5% | 2.0% |
| Net Profit YoY | -26.4% | -8.8% |
| EPS (diluted) | $1.13 | $1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | $781.9M | ||
| Q3 25 | $961.1M | $782.4M | ||
| Q2 25 | $966.0M | $768.8M | ||
| Q1 25 | $887.3M | $760.8M | ||
| Q4 24 | $848.1M | $766.8M | ||
| Q3 24 | $909.3M | $748.3M | ||
| Q2 24 | $910.1M | $734.2M | ||
| Q1 24 | $915.4M | $730.8M |
| Q4 25 | $74.3M | $382.1M | ||
| Q3 25 | $127.9M | $289.1M | ||
| Q2 25 | $111.7M | $192.4M | ||
| Q1 25 | $78.8M | $256.6M | ||
| Q4 24 | $100.9M | $419.1M | ||
| Q3 24 | $100.0M | $143.4M | ||
| Q2 24 | $90.5M | $177.5M | ||
| Q1 24 | $83.1M | $295.8M |
| Q4 25 | 11.0% | 50.6% | ||
| Q3 25 | 14.2% | 38.5% | ||
| Q2 25 | 14.9% | 26.6% | ||
| Q1 25 | 12.8% | 35.7% | ||
| Q4 24 | 14.2% | 57.2% | ||
| Q3 24 | 15.2% | 20.1% | ||
| Q2 24 | 13.8% | 25.3% | ||
| Q1 24 | 12.2% | 42.0% |
| Q4 25 | 7.7% | 48.9% | ||
| Q3 25 | 13.3% | 36.9% | ||
| Q2 25 | 11.6% | 25.0% | ||
| Q1 25 | 8.9% | 33.7% | ||
| Q4 24 | 11.9% | 54.7% | ||
| Q3 24 | 11.0% | 19.2% | ||
| Q2 24 | 9.9% | 24.2% | ||
| Q1 24 | 9.1% | 40.5% |
| Q4 25 | $1.13 | $1.01 | ||
| Q3 25 | $1.92 | $0.76 | ||
| Q2 25 | $1.67 | $0.50 | ||
| Q1 25 | $1.17 | $0.67 | ||
| Q4 24 | $1.48 | $1.10 | ||
| Q3 24 | $1.48 | $0.38 | ||
| Q2 24 | $1.34 | $0.47 | ||
| Q1 24 | $1.23 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $55.9M |
| Total DebtLower is stronger | $1.1B | $8.2B |
| Stockholders' EquityBook value | $2.7B | $11.0B |
| Total Assets | $5.3B | $20.7B |
| Debt / EquityLower = less leverage | 0.43× | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | $55.9M | ||
| Q3 25 | $264.8M | $93.1M | ||
| Q2 25 | $169.8M | $31.3M | ||
| Q1 25 | $136.8M | $39.8M | ||
| Q4 24 | $226.2M | $62.3M | ||
| Q3 24 | $327.9M | $28.6M | ||
| Q2 24 | $223.9M | $38.3M | ||
| Q1 24 | $201.1M | $44.5M |
| Q4 25 | $1.1B | $8.2B | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | $8.2B | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
| Q4 25 | $2.7B | $11.0B | ||
| Q3 25 | $2.8B | $11.1B | ||
| Q2 25 | $2.7B | $11.0B | ||
| Q1 25 | $2.5B | $11.0B | ||
| Q4 24 | $2.5B | $11.0B | ||
| Q3 24 | $2.5B | $10.9B | ||
| Q2 24 | $2.4B | $11.0B | ||
| Q1 24 | $2.3B | $11.1B |
| Q4 25 | $5.3B | $20.7B | ||
| Q3 25 | $5.1B | $21.1B | ||
| Q2 25 | $4.9B | $21.0B | ||
| Q1 25 | $4.5B | $20.6B | ||
| Q4 24 | $4.4B | $20.8B | ||
| Q3 24 | $4.6B | $20.9B | ||
| Q2 24 | $4.5B | $19.8B | ||
| Q1 24 | $4.4B | $19.9B |
| Q4 25 | 0.43× | 0.75× | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | 0.74× | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $387.0M |
| Free Cash FlowOCF − Capex | $96.9M | — |
| FCF MarginFCF / Revenue | 10.1% | — |
| Capex IntensityCapex / Revenue | 9.0% | — |
| Cash ConversionOCF / Net Profit | 2.47× | 1.01× |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | $387.0M | ||
| Q3 25 | $177.6M | $476.7M | ||
| Q2 25 | $126.0M | $359.5M | ||
| Q1 25 | $82.7M | $425.5M | ||
| Q4 24 | $178.2M | $354.2M | ||
| Q3 24 | $229.3M | $401.4M | ||
| Q2 24 | $143.6M | $396.9M | ||
| Q1 24 | $92.3M | $421.0M |
| Q4 25 | $96.9M | — | ||
| Q3 25 | $114.3M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $25.9M | — | ||
| Q4 24 | $112.2M | — | ||
| Q3 24 | $162.7M | — | ||
| Q2 24 | $75.4M | — | ||
| Q1 24 | $16.7M | — |
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 9.0% | — | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 7.5% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.47× | 1.01× | ||
| Q3 25 | 1.39× | 1.65× | ||
| Q2 25 | 1.13× | 1.87× | ||
| Q1 25 | 1.05× | 1.66× | ||
| Q4 24 | 1.77× | 0.85× | ||
| Q3 24 | 2.29× | 2.80× | ||
| Q2 24 | 1.59× | 2.24× | ||
| Q1 24 | 1.11× | 1.42× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
EQR
Segment breakdown not available.
